Joint Pain Injections Market Size, Share & COVID-19 Impact Analysis, By Product (Corticosteroid Injections, Platelet Rich Plasma Injections, and Others); By Joint Type (Knee and Ankle, Hip, Shoulder and Elbow, and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2021-2028

Updated On: March, 2023

The global joint pain injections market size was USD 4.51 billion in 2020 and is expected to grow from USD 4.71 billion in 2021 to USD 7.95 billion in 2028, at a CAGR of 7.8% in the 2021-2028 period. Based on our analysis, the global market exhibited a significant decline of -7.5% in 2020. The global impact of COVID-19 was unprecedented and staggering, with the market witnessing a negative demand across all regions amid the pandemic. The sudden rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over

The increasing prevalence of osteoarthritis and musculoskeletal disorders in the general population is responsible for the increasing number of patients suffering from joint pain and related complications. This factor increases the demand for intra-articular injections for the treatment of joint pain in developed and emerging countries.

Moreover, growing number of treatments is attributed to the favorable reimbursement policies in developed countries. Additionally, the growing awareness about the benefits of intra-articular injections in treating joint pain is responsible for the increasing demand for joint injections.

• For instance, according to the data published by Versus Arthritis, it was estimated that around 8.8 million people in the U.K. had undergone osteoarthritis treatment in the year 2019.

Deferral of Elective Procedures During Covid-19 to Decline Revenues Generation in 2020 

The emergence of COVID-19 significantly hampered the demand for joint pain injections worldwide. Leading players operating in the market reported a decline in their revenues from the sales of joint pain injections due to the COVID-19 pandemic.

The significant decline in the revenues for the joint pain injections industry was attributed to the decline in patient visits, reallocation of healthcare resources for COVID-19 management, and disruption in the supply chain of key players operating in the market. Additionally, healthcare facilities postponed non-covid related activities and elective surgical procedures, including procedures for treating joint pain.

• For instance, according to the research paper published in the Journal of Bone and Joint Surgery, the daily activities of orthopedic surgeons were hampered by 72.6% of the institutions during the first half of 2020. It also stated that around 50% of orthopedic practitioners were shifted from routine orthopedic work to COVID-19 patient management.

Moreover, there was a disruption in business activities such as manufacturing and logistics due to the lockdown restrictions in major markets for joint pain injections. Therefore, a significant decline in growth was reported by major players in 2020. For instance, Bioventus Inc., recorded a 6% decline in revenues from OA joint pain treatment and joint preservation business segment in 2020 compared to 2019. The decline in  revenues from joint pain injections was attributed to a decrease in the number of procedures performed in 2020.

LATEST TRENDS

Request a Free sample to learn more about this report.

Increasing Shift Towards Single Injection Therapy and Plasma Matrix Therapy to Present  Lucrative Market Opportunities

Increasing geriatric population and rising prevalence of arthritis boosts the demand for effective treatment options for joint pain. Major players operating in the joint pain injections industry are involved in the development of innovative treatment solutions such as platelet-rich plasma injections plasma matrix therapy. Additionally, ongoing research activities highlight benefits associated with novel treatments, which supports the adoption of innovative products.

• For instance, according to the National Library of Medicine, a study revealed that the anti-inflammatory effect of platelet-rich plasma therapy for joint pain associated with osteoarthritis significantly reduced pain.

The currently marketed drugs in the joint pain injections industry such as hydrocortisone injections are generally administered in three or five injections. This factor is responsible for higher treatment costs and lack of adherence to the treatment. Therefore, key players operating in the market introduce single injection therapy. Single injection therapy is a more effective and -saving option for treating joint pain. Also, according to RxList Inc., Monovisc, which is a hyaluronic acid visco-supplement single injection used for the therapy of joint pain associated with osteoarthritis, is equivalent to three injection therapy of Orthovisc by Anika Therapeutics, Inc. Therefore, the introduction of innovative products in the market is responsible for increasing shift of customers from three and five injections to single injection therapy.

DRIVING FACTORS

Growing Prevalence of Osteoarthritis and Obesity in General Population to Propel  ProductDemand

Many factors, such as growing geriatric population and sedentary lifestyle in developed and developing countries are responsible for the high prevalence of musculoskeletal disorders such as osteoarthritis.

• For instance, according to the World Health Organization (WHO) estimations, approximately 1.71 billion people worldwide were suffering from musculoskeletal disorders in 2020. Also, according to the  Healio’s estimations, around 303.1 million people globally were suffering from osteoarthritis in 2018.

Thus, the presence of a large patient pool suffering from osteoarthritis and the growing awareness for early diagnosis & treatment is responsible for increasing demand for pain treatment products, including injections for joint pain. Further, increasing per capita expenditure on healthcare in developed countries and new product launches by market players bolsters the demand for intra-articular injections in the global market. 

RESTRAINING FACTORS

High Cost of Injections and Lack of Reimbursement Policies to Limit Adoption in Emerging Countries

The rising prevalence of musculoskeletal disease and the surge in demand for effective treatment are propelling joint pain injections’ demand. Moreover, high costs of joint injections and stringent regulations for product approvals are major factors estimated to restrict market growth.

• For instance, in March 2021, the U.S. FDA rejected Pfizer Inc. Eli Lilly and Company’s tanezumab for osteoarthritis pain due to some risk-benefit doubts. The FDA’s Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) ruled that while clinical data suggested tanezumab can benefit patients with OA pain, the associated risk for joint destruction, or rapidly progressing osteoarthritis and other safety outcomes were more prominent, even with the proposed modification efforts.

Moreover, the lack of awareness about these products in developing countries is accountable for the lower adoption of intra-articular injections in the treatment of joint pain. Furthermore, the lack of reimbursement policies for intra-articular injections in these countries is restraining the market's growth.

SEGMENTATION

By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Clinically Proven Benefits Increases Preference towards HA-based Injections Globally

Based on product, the global market is segmented into corticosteroid injections, hyaluronic acid (HA) injections, platelet-rich plasma injections, and others.

The HA injections segment accounted for the largest joint pain injections market share, globally. The growing number of patients with osteoarthritis pain and  the rising awareness about clinical benefits offered by HA injections over corticosteroids is responsible for the growing adoption of these products among osteoarthritis patients with moderate to severe pain.

Additionally, the rising number of product approvals for HA injections, also referred to as viscosupplements/gel injections are anticipated to further augment the segment's growth in near future.

• For instance, in March 2021, Seikagaku Corporation’s JOYCLU received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for the treatment of osteoarthritis.

On the other hand, the corticosteroid injections segment held the second largest market share during the 2021-2028. The comparatively lower annual cost of corticosteroids leads to increaseddemand for corticosteroid injections during the forecast period.

The platelet-rich plasma injections segment is anticipated to register higher CAGR than other segments due to the increasing number of clinical trials to establish the efficiency of platelet-rich plasma therapy for pain management among osteoarthritis patients and their projected approvals. Others product segment includes trigger point injections (lidocaine, Marcaine), botox injections, placental tissue matrix (PTM) injections.

By Joint Type Analysis

Higher Prevalence of Joint Pain in Knee & Ankle is Responsible for Higher Share of the Segment

The market is segmented into knee and ankle, hip, shoulder and elbow, and others based on joint type.

The knee and ankle segment is projected to account for the largest market share during the in near future. The increasing demand for intra-articular injections for the management of knee pain is attributed to the rising cases of knee osteoarthritis.

• 
  
  
  
  • According to a study published by the National Center for Biotechnology Information in 2020, it was observed that the global prevalence of knee osteoarthritis (OA) was 16.0% among people aged 15 years and above and was 22.9% among individuals aged 40 years and above.
  
  
  
  

Moreover, the strong product portfolio offered by key players for the treatment of pain associated with knee osteoarthritis, combined with the growing number of patients undergoing treatment, is responsible for the rising demand for injections for pain management and treatment of knee joints.

On the other hand, the hip joint segment accounted for second-largest share in the market. The growth of this segment is attributed to the increasing incidence of hip osteoarthritis among the global population coupled with the growing number of clinical trials for this indication. 

By Distribution Channel Analysis

Increasing Inpatient Admissions Led to the Dominance of Hospital Pharmacies Segment during 2021-2028

The global joint pain injections market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on distribution channel.

The hospital pharmacies segment held the largest share in the global market in 2020. The dominance of the hospital pharmacies segment is attributed to the growing hospitalization rate of patients suffering from orthopedic conditions across the globe. Additionally, the adequate reimbursement policies offered by healthcare facilities have been pivotal in higher intra-articular injection sales by hospital pharmacies in the market. The retail pharmacies segment accounted for a significant market share in the global market due to the strong network of retail pharmacy chains in developed countries.

On the other hand, the online distribution channel segment is anticipated to record a higher CAGR than the other subsegment. The higher growth of online channels is attributed to evolving regulatory policies for online sales of prescription drugs in developed countries and the entry of leading e-pharmacy players in the market.  

• For instance, Flipkart, a leading e-commerce platform in India, plans to collaborate with PharmEasy, an emerging e-pharmacy player in the country, to cater to the lucrative segment. Similarly, Amazon India has laid down plans for entering the lucrative market during the next few years.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

North America to Hold Highest Market due to Well-Established Reimbursement Policies

The North American region dominated the global market with a contribution of USD 1.76 billion in the global market in 2020. The growing patient population suffering from joint pain, well-established reimbursement policies for intra-articular injections, and the increasing focus of market players in catering to the demand present in the U.S. and Canadian markets are the major factors responsible for driving the growth of North American market.

• For instance, according to the Osteoarthritis Research Society International (ORSI) data published in 2018, an estimated prevalence of osteoarthritis (OS) in North America was around 4.15% among the general population.

Europe region accounted for the second-largest market share in the global market since a large patient pool suffer from pain associated with musculoskeletal disorders such as arthritis. Further, the presence of skilled professionals and the introduction of novel intra-articular pain injections in the European markets is expected to incite growth.

On the other hand, Asia Pacific joint pain injections market growth is expected to register the highest growth rate during the 2021-2028. The growing prevalence of osteoarthritis and the introduction of viscosupplements by market players in the region are driving the market growth in Asian countries. Moreover, the rising awareness about the innovative treatments for joint pain in the region also provides favorable conditions for the market's growth.

Latin America and the Middle East and Africa regions held a lower share in the global market. However, the increasing cases of arthritis, and the rising adoption of technologically advanced solutions for pain management in these regions are expected to drive the market growth in near future.

KEY INDUSTRY PLAYERS

Strong Portfolio of Sanofi, Zimmer Biomet, Bioventus Inc., Anika Therapeutics, Inc. to Boost Market Position

The joint pain injections industry is consolidated with key players, such as Sanofi, Zimmer Biomet, Bioventus Inc. Anika Therapeutics, Inc. The dominance of these players is attributed to the strong distribution network, strategic collaborations and robust product portfolio of intra-articular devices. The key companies operating in the market are developing innovative products to gain a competitive advantage over other market players.           

• For instance, In March 2019, Seikagaku Corporation launched HyLink, a single-injection viscosupplement to treat knee osteoarthritis and subsequently reduce the pain for 26 weeks.

Moreover, the other market players, including Flexion Therapeutics Inc., Ferring B.V., Seikagaku Corporation, Wright Medical Group N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., are focusing on expansion plans to cater to developing markets across the globe.

LIST OF KEY COMPANIES PROFILED:

• Seikagaku Corporation (Tokyo, Japan)


• Flexion Therapeutics Inc. (Burlington, U.S.)


• Dr. Reddy’s Laboratories Ltd. (Hyderabad, India)


• Zimmer Biomet (Warsaw, U.S.)


• Wright Medical Group N.V. (Staines-upon-Thames, U.K.)


• Sanofi (Paris, France)


• Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)


• Anika Therapeutics, Inc. (Bedford, U.S.)


• Bioventus Inc.(Durham, U.S.)


• Ferring B.V.(Saint-Prex, Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• December 2019 - Flexion Therapeutics Inc. announced the U.S. FDA approval of supplemental New Drug Application to update the product label of ZILRETTA and give more clear information about the product.


• July 2019- Teva Pharmaceutical Industries Ltd. announced the launch of 1% Sodium Hyaluronate in the U.S. market after getting approval from the Center for Devices and Radiological Health of the U.S. FDA. This product is used to treat pain associated with osteoarthritis in the knee.

REPORT COVERAGE

An Infographic Representation of Joint Pain Injections Market

View Full Infographic

To get information on various segments, share your queries with us

The market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, products, joint type, and distribution channels. Besides this, it offers insights into the trends in the global market and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market's growth over recent years.

Report Scope & Segmentation